Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
4(33%)
Results Posted
20%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
4
33%
Ph phase_2
8
67%

Phase Distribution

4

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
4(33.3%)
Phase 2Efficacy & side effects
8(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

4

trials recruiting

Total Trials

12

all time

Status Distribution
Active(4)
Completed(5)
Terminated(1)
Other(2)

Detailed Status

Completed5
Recruiting3
unknown2
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
4
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (33.3%)
Phase 28 (66.7%)

Trials by Status

recruiting325%
completed542%
active_not_recruiting18%
unknown217%
terminated18%

Recent Activity

4 active trials
Showing 5 of 12
recruitingphase_2

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

NCT07176312
recruitingphase_1

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05458219
terminatedphase_2

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

NCT05998447
recruitingphase_2

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

NCT05065957
completedphase_2

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

NCT03647969
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07176312Phase 2

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

Recruiting
NCT05458219Phase 1

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting
NCT05998447Phase 2

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Terminated
NCT05065957Phase 2

Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer

Recruiting
NCT03647969Phase 2

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

Completed
NCT03720678Phase 1

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Completed
NCT04543695Phase 2

A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer

Active Not Recruiting
NCT03503630Phase 2

Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma

Unknown
NCT02504333Phase 1

Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma

Completed
NCT05116891Phase 1

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Completed
NCT00904839Phase 2

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

Completed
NCT00591045Phase 2

Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12